Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
AllianceBernstein L.P. amended its Schedule 13G to report 147,327 shares of PROCEPT BioRobotics Corp Common Stock held in discretionary client accounts. The filing states AllianceBernstein has sole voting power for 146,027 shares and sole dispositive power for 147,327 shares, representing 0.3% of the class. The amendment is signed on 05/15/2026.
PROCEPT BioRobotics Corp executive Barry L. Templin, EVP and Chief Technology Officer, filed an initial ownership report showing his equity stake in the company. The filing lists 69,311 shares of Common Stock held directly and 56,457 shares held indirectly through the Templin Trust.
It also details several stock options to buy Common Stock, including 29,615 underlying shares at an exercise price of $25.35 per share expiring in 2036 and 34,591 underlying shares at $5.18 per share expiring in 2030. Footnotes describe these as time‑vested grants with monthly vesting schedules tied to continued service.
PROCEPT BioRobotics reported first-quarter 2026 revenue of $83.1 million, up 20% from $69.2 million a year earlier, driven by higher system sales, consumables, and service, mainly in the United States.
Gross margin improved slightly to 65%, but the company’s net loss widened to $31.6 million, reflecting increased research, sales, and administrative spending to support growth. Operating cash outflow was $38.1 million, and cash and cash equivalents totaled $245.6 million with $52.0 million of term debt outstanding. The global installed base reached 971 robotic systems, including 765 in the U.S.
PROCEPT BioRobotics Corp ownership disclosure: Vanguard Capital Management reports beneficial ownership of 2,820,430 shares of common stock, representing 5% of the class. The filing states Vanguard has sole dispositive power over 2,820,430 shares and sole voting power over 421,363 shares. The filing notes these holdings include securities held for Vanguard funds and managed accounts.
PROCEPT BioRobotics reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose 20% year over year to $83.1 million, driven by higher U.S. system and handpiece sales and 25% growth in international revenue. Gross margin improved to 65%, up from 64% a year ago and 61% in the prior quarter.
U.S. Aquablation procedures reached about 12,200, up roughly 30% year over year, and the U.S. install base grew to 765 systems, a 40% increase. Despite this growth, operating expenses increased to $86.6 million, leading to a net loss of $31.6 million and Adjusted EBITDA loss of $18.1 million. The company ended the quarter with about $249 million in cash and reaffirmed 2026 guidance, including revenue of $390–$410 million and an Adjusted EBITDA loss of $30–$17 million. PROCEPT also highlighted recent FDA clearance of its second-generation FirstAssist AI software, further enhancing its HYDROS robotic system.
PROCEPT BioRobotics Corp reported initial insider holdings for Chief Strategy and Marketing Officer Pooja Sharma. She beneficially owns 87,559 shares of Common Stock directly, including restricted stock units that vest over time as long as she continues as a service provider.
She also holds stock options covering 29,615 shares of Common Stock at an exercise price of $25.35 per share, expiring on March 4, 2036, and options for 85,929 shares at an exercise price of $31.92 per share, expiring on November 6, 2035. These options vest gradually over several years, contingent on continued employment.
PROCEPT BioRobotics is calling a fully virtual 2026 annual stockholder meeting on June 9, 2026 at 1:00 p.m. Eastern Time. Stockholders will vote on electing three Class II directors (Antal Desai, Mary Garrett and Frederic Moll, M.D.), ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving, on an advisory basis, executive compensation.
The record date is April 10, 2026, and all voting can be done online, by phone, mail or during the webcast. The proxy also reviews 2025 performance, including revenue of $308.1 million (up from $224.5 million in 2024), approximately 43,300 U.S. procedures, 718 installed systems and a 64% gross margin, as well as a leadership transition to CEO Larry L. Wood.
PROCEPT BioRobotics Corp ownership disclosure: The Vanguard Group filed an Amendment No. 4 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries and divisions to report separately; Vanguard states those units pursue the same investment strategies previously used.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
PROCEPT BioRobotics Corp executive vice president and chief legal officer Alaleh Nouri reported selling a total of 5,363 shares of common stock in two open‑market transactions. The shares were sold at weighted average prices of $25.8193 for 3,031 shares and $26.1460 for 2,332 shares.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. After the transactions, Nouri directly holds 105,354 shares, indicating the sales represent a relatively small portion of her overall position.
Alalah Nouri filed a Form 144 notice proposing the sale of company common stock derived from RSU vesting. The filing lists proposed amounts of 2,820, 1,996 and 547 shares tied to RSU vesting dates in March 2026, and shows 3,243 shares sold on 03/10/2026.